Produce the right data with a risk-based approach to innovative clinical trial design
To best serve patients and clinical trial sponsors, we take a risk-focused approach to innovative clinical solutions including adaptive trial design, planning, and execution. Throughout each of these stages, our team continually assesses risk to control it and adapt as we move forward. Evaluation begins with risks to critical data and processes, as well as country selection, site-specific variables, and data integrity.
This upfront risk evaluation informs the entire study plan. We bring clinical expertise to portfolio- and study-level planning — harnessing the power of data-driven insights, historical knowledge, database intelligence, and thorough scenario planning to deliver clinical solutions tailored to each program's risk profile.
A balanced study design
A well-designed protocol accounts for patient safety, data integrity, and operational feasibility. Our team of medical, biostatistical, and operational experts help you balance these sometimes-competing priorities.
Today, the distinction between trial phases has blurred, with more flexibility in trial design — often combining multiple studies in a single, overlapping protocol. Flexible, adaptive designs allow for accelerated development through the ability to rapidly declare one or more treatments superior, drop treatments for futility, or dynamically add new treatments to be tested. However, adaptive approaches require expert biostatistical oversight, and close collaboration between clinical operations, data management, medical experts, and project leadership for design, planning and execution. As decentralized trial designs increase in adoption, we look at the needs and requirements of your trials to see how patients may benefit from DCT components.
During protocol development, our patient engagement team makes recommendations for minimizing patient burden by reviewing the frequency and duration of treatments, invasiveness of procedures, and any participation requirements that are likely to pose compliance challenges, among other factors.
Trial execution around the world
Our global reach for adaptive trials extends across the Americas, Europe and Asia. We cover the whole globe and are one of the CROs in Asia, with a presence in Japan, China, Korea, and India. From designing and running pivotal trials, to navigating regulatory hurdles, our clinical solutions are ready to meet your needs anywhere with attention and efficiency, providing:
- A focused team handling all study start-up activities
- Advanced resource planning tools that dynamically match resource needs at every stage based on a range of variables
- Multidisciplinary project management to centralize efforts and ensure transparency and collaboration
- Data stream integration, with efficient workflows to ensure regulatory-grade data at every handoff
- Medical writing expertise to handle applications and other key documents
Industry leaders in patient inclusion
Global regulators are requiring trial populations to include participants from underrepresented racial and ethnic populations. At Parexel, patient inclusion is a priority in considerations of race, gender, age, ability, economic status, and more. We have the experience and proven strategies to make your trials more inclusive.
The path to commercialization
As your product transitions from development to commercialization, our late-phase experts provide dedicated project management, with global resources to customize solutions for local markets.
We have the regulatory expertise to manage the final lap of the journey — filing the new drug application (NDA) or market authorization submissions. This highly specialized expertise relieves your team of this complicated and time-consuming responsibility.
Our specialists tailor scientific, strategic, and market solutions to meet your business goals. We help you develop a market access strategy that will build value quickly, while closely monitoring long-term effects and safety.
Our experts
Browse our latest insights
Want to hear from our experts on the latest industry topics? Visit our Insights Center to read, watch, and listen.
Frequently asked questions
Phase IIB-IV clinical trials are a combined classification that bridges two distinct phases of clinical drug development:
Phase IIB Trials
Phase IIB (sometimes written as Phase 2B) trials are an extended phase of efficacy and safety testing, typically conducted after initial Phase II results show promise. Key characteristics include:
- Purpose: Continue evaluating drug efficacy and safety in a larger patient population
- Patient Population: 300-1,000+ patients with the target disease
- Duration: Can last several months to 2+ years
- Focus:
- Dose optimization and confirmation
- Efficacy measurement using primary endpoints
- Safety monitoring in a broader population
- Identification of side effects and adverse reactions
- Preliminary assessment of effectiveness for regulatory submission
Phase III Trials
Phase III trials are large-scale confirmatory studies designed to verify efficacy and monitor adverse reactions. Key characteristics include:
- Purpose: Confirm the drug's effectiveness, monitor side effects, and compare it to standard treatments
- Patient Population: 1,000-5,000+ patients across multiple locations/countries
- Duration: 1-4 years
- Focus:
- Confirmation of efficacy in the target population
- Comparison with placebo or standard treatment
- Collection of data for regulatory approval (FDA, EMA, etc.)
- Monitoring of long-term safety
Phase IV Trials
Phase IV trials (Post-Marketing Surveillance) occur after regulatory approval:
- Purpose: Monitor long-term safety and effectiveness in the general population
- Patient Population: Thousands of patients in real-world settings
- Duration: Ongoing after drug approval
- Focus:
- Long-term safety monitoring
- Detection of rare side effects
- Identification of new uses or benefits
- Comparison with other treatments in clinical practice
Why Combined Classification?
The "Phase IIB-IV" designation sometimes appears in regulatory or clinical contexts to indicate a continuum of testing from late-stage efficacy confirmation through post-marketing surveillance, emphasizing the progression from controlled trials to real-world evidence collection.
An adaptive, risk-based approach represents a modern evolution in clinical trial methodology that offers significant improvements over traditional fixed designs. Here's how:
Adaptive Trial Design Benefits
Flexibility and Efficiency
- Allows pre-planned modifications to the trial based on interim data without compromising statistical integrity
- Reduces trial duration by enabling early stopping for efficacy or futility
- Optimizes sample size based on emerging data rather than relying solely on initial assumptions
- Permits dose adjustments or arm modifications mid-trial
Cost Optimization
- Avoids wasting resources on ineffective treatments or doses
- Reduces patient exposure to ineffective therapies
- Decreases overall trial costs through more efficient resource allocation
- Minimizes unnecessary patient recruitment
Improved Decision-Making
- Provides real-time data insights for go/no-go decisions
- Enables faster identification of promising treatment pathways
- Allows for seamless transitions between trial phases
- Supports more informed regulatory interactions
Risk-Based Approach Benefits
Targeted Risk Management
- Focuses monitoring and oversight on high-risk areas (safety, data integrity, compliance)
- Allocates resources proportionally to identified risks
- Enables risk-stratified patient monitoring
- Reduces unnecessary oversight of low-risk activities
Patient Safety Enhancement
- Enables rapid response to safety signals through adaptive stopping rules
- Allows for real-time safety monitoring and intervention
- Supports population-specific risk assessments
- Facilitates early identification of at-risk subgroups
Regulatory Alignment
- Aligns with regulatory guidance on adaptive designs and risk-based approaches
- Supports ICH E19 guidance on adaptive clinical trial designs
- Demonstrates scientific rigor and transparency
- Facilitates more productive regulatory interactions
Combined Adaptive + Risk-Based Approach
When integrated together, these approaches create:
- Intelligent Resource Allocation: High-risk areas receive intensive monitoring while low-risk areas operate with lighter oversight
- Dynamic Trial Evolution: Trials can adapt their risk management strategies as new data emerges
- Patient-Centric Design: Balances scientific rigor with patient safety and minimizes unnecessary exposure
- Operational Excellence: Optimizes timelines, costs, and quality simultaneously
Practical Applications
- Seamless Phase Transitions: Adaptive designs enable smoother transitions from Phase IIB to Phase III
- Biomarker-Driven Designs: Risk-based approaches identify and focus on biomarker-positive populations
- Dose-Finding Studies: Adaptive methods optimize dose selection more efficiently
- Complex Populations: Better accommodate heterogeneous patient populations with varying risk profiles
This approach represents a shift from a "one-size-fits-all" model to a more sophisticated, data-driven strategy that improves outcomes for patients, sponsors, and the drug development process overall.
Parexel is committed to making clinical trials more inclusive and accessible to all patients regardless of race, gender, age, ability, or economic status.
We address barriers to participation by utilizing trial sites in underserved communities, providing educational materials to dispel misconceptions, and designing trials that account for common obstacles such as lack of time and transportation.
Through our Patient Insights service, Parexel gathers feedback from patients, staff, and providers during the trial design phase to identify potential challenges and implement solutions. This includes reducing patient burden through adjusted testing schedules, using more inclusive language in materials, and offering virtual assessment options.